Neurology · Orlando area, FL
Neurology studies in Orlando area, FL
77 recruiting studies have a site in the Orlando area. This page includes nearby cities such as Winter Park, Kissimmee, Altamonte Springs, Sanford.
77 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Lakeland, FL + 35 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Altamonte Springs, FL + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sanofi
- Location
- Altamonte Springs, FL + 33 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 2
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Alnylam Pharmaceuticals
- Location
- Maitland, FL + 3 other US sites
- Eligibility basics
- Ages 40–55
- RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Hoffmann-La Roche
- Location
- Maitland, FL + 11 other US sites
- Eligibility basics
- Ages 55–80
- RecruitingPhase 3
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
Epygenix
- Location
- Miami, FL + 16 other US sites
- Eligibility basics
- Ages 2–55
- RecruitingPhase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie
- Location
- Gulf Breeze, FL + 28 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
- Location
- Maitland, FL + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
Aspeya, Inc.
- Location
- Orlando, FL + 19 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
Teikoku Pharma USA, Inc.
- Location
- Daytona Beach, FL + 7 other US sites
- Eligibility basics
- Any age listed
- RecruitingPhase 2
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Eli Lilly and Company
- Location
- Atlantis, FL + 29 other US sites
- Eligibility basics
- Ages 55–85
- RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Regeneron Pharmaceuticals
- Location
- Cutler Bay, FL + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
Lighthouse Pharmaceuticals, Inc.
- Location
- Atlantis, FL + 36 other US sites
- Eligibility basics
- Ages 55–80
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Daytona Beach, FL + 31 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Bristol-Myers Squibb
- Location
- Atlantis, FL + 23 other US sites
- Eligibility basics
- Ages 60–85
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Atlantis, FL + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Appello Pharmaceuticals, Inc.
- Location
- Boca Raton, FL + 29 other US sites
- Eligibility basics
- Ages 30–80
- RecruitingPhase 1/Phase 2
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
NKGen Biotech, Inc.
- Location
- Maitland, FL + 5 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Neuron23 Inc.
- Location
- Boca Raton, FL + 43 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
Study of EVO756 in Adults With Migraine
Evommune, Inc.
- Location
- Jacksonville, FL + 32 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 2
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
Supernus Pharmaceuticals, Inc.
- Location
- Gulf Breeze, FL + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
MapLight Therapeutics
- Location
- Boca Raton, FL + 32 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
- Location
- Maitland, FL + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 4
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Genentech, Inc.
- Location
- Maitland, FL + 3 other US sites
- Eligibility basics
- Ages 18–65
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.